A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

ABBV-383, Bortezomib (BTZ), Carfilzomib (Kyprolis), Dexamethasone, Elotuzumab, Pomalidomide (POM)(CC-4047), Selinexor

Principal Investigator(s):

Baljevic, Muhamed

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

06-16-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTPCL23493

National Clinical Trial ID:

NCT06158841

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available